Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polymyxin B plasma and lung penetration in HAP/VAP due to carbapenem-resistant Gram-negative bacilli
ChiCTR2200062227Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Jul 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polymyxin B in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), Gram-negative pneumonia and 1 more, sponsored by Huashan Hospital. Primary endpoints: Polymyxin B concentration and lung penetration in blood and pulmonary epithelial lining fluid and Pharmacokinetic characteristics of polymyxin B in plasma. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
polymyxin B
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Gram-negative pneumoniapneumonia
Beyond the preview
Go deeper on ChiCTR2200062227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062227.